Published in Blood Weekly, July 20th, 2006
According to a study from the United States, "Our goal was to evaluate whether systemic administration of NV1042, an interleukin-12 (IL-12) - expressing oncolytic herpes simplex virus, and its noncytokine parental vector NV1023 are effective against pre-existing metastatic prostate cancer in an immunocompetent mice model.
"Metastatic TRAMP-C2 lung tumors established in C57Bl/6 or nude mice were treated on day 21 with four i.v. administrations of NV1042 or NV1023 and sacrificed on day 42 to assess virus efficacy and the potential mechanism of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.